在研究白血病导向治疗过程中,作者获得一组抗髓系单克隆抗体(McAb),分别命名为HIM又名(HI98),HIM_4、HIM_5、HI_115、HI_117和HI_43。 HIM_1、HIM_4和HIM_5是一组髓系特异性McAb,仅与粒、单细胞系(HL_60、K_562、U_937和KG_1)反应,可与80％外周血和50％骨髓中的粒和单核细胞反应;但不与淋巴细胞系、外周血淋巴细胞、红细胞和血小板反应。三种McAb与骨髓不同分化阶段的髓系细胞的反应模式不同,其相应抗原在急 In the study of leukemia-directed therapy, the authors obtained a group of anti-myeloid monoclonal antibodies (McAbs) named as HIM (HI98), HIM_4, HIM_5, HI_115, HI_117 and HI_43, respectively. HIM_1, HIM_4 and HIM_5 are a group of myeloid-specific McAbs that react only with granulocytes, single cell lines (HL_60, K_562, U_937 and KG_1) and react with granulocytes and monocytes in 80% of peripheral blood and 50% of bone marrow ; But not with lymphocyte lines, peripheral blood lymphocytes, red blood cells and platelets. Three kinds of McAbs with different differentiation stages of bone marrow myeloid cells in different response patterns, the corresponding antigen in the emergency